A tyrosine kinase inhibitor.

Phase of research

Potential treatment - pre-clinical evidence

How it helps


Drug status

Used to treat other disease

Supporting references
Contradictory references
AI-suggested references
Clinical trials

General information

Sunitinib is an indole derivate receptor protein-tyrosine kinase inhibitor. It manifests antineoplastic and neuroprotective activities. Sunitinib also acts as a vascular endothelial growth factor receptor antagonist and an immunomodulator (ChEBI).

Sunitinib on DrugBank
Sunitinib on PubChem
Sunitinib on Wikipedia

Marketed as



Structure image - Sunitinib


Supporting references

Link Tested on Impact factor Notes Publication date
Sunitinib reduces the infection of SARS-CoV, MERS-CoV and SARS-CoV-2 partially by inhibiting AP2M1 phosphorylation
Small molecule In vitro
ACE2-HeLa cells 6.26

Inhibition of AP2M1 phosphorylation in vitro, which likely leads to inhibition clathrin-dependent SARS-CoV-2 cell entry, at concentrations that are achieved via standard therapeutic dosing.

Heparan sulfate assists SARS-CoV-2 in cell entry and can be targeted by approved drugs in vitro
Polysaccharide Small molecule In vitro
ACE2-GFP HEK293T cells; Calu-3 cells; Vero E6 cells; SARS-CoV-2 pseudotyped particles 6.26

Inhibits SARS-CoV-2 pseudovirus cell entry with IC50 of 10 μM in ACE2-GFP HEK293T cells. At 10 μM concentration the drug reduced virus-induced cytopathic effect in Vero E6 cells by ca. 30%. It might act through actin cytoskeleton metabolism disregulation.

Machine learning identifies molecular regulators and therapeutics for targeting SARS-CoV2-induced cytokine release
Spike protein Spike variant Small molecule In vitro Mechanism In silico Al
THP1 cells-derived macrophages 11.43

SARS-CoV-2 (WT/alpha/beta/delta variant) Spike protein’s N-terminal domain induced inflammation in an in vitro model. This inflammation was partially inhibited by the compound. 


AI-suggested references